Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Brackett, WI

Cameron Brackett, Pewaukee, WI US

Patent application number	Description	Published
20100184400	Localized Personal Emergency Response System - A personal emergency response system oriented to mobile individuals uses cell phones or other wireless devices as sources of an emergency indicating signal. A personal profile associated with that signal can be evaluated, along with location information to determine which emergency device(s) should be activated and which local messages should be produced to alert other individuals in the area as to the existence of an emergency.	07-22-2010
20100185114	Electrode Placement for Remote Monitoring - A method of placing ECG electrodes in an environment where persons of limited training are available includes making a trial placement of the electrodes. Then, testing the electrodes and evaluating signals from the electrodes as a result of the testing. Verbal or visual feedback can be provided to the person placing the electrodes so that placed electrodes could be adjusted as needed.	07-22-2010

Charles Cameron Brackett, Pewaukee, WI US

Patent application number	Description	Published
20110064283	OCR INTERFACE TO SINGLE RESULT DIAGNOSTIC INTERFACE - A method and apparatus are provided. The method includes the steps of an imaging device capturing an image of a display of a medical instrument, an image processor determining a location of a patient biometric measurement within the image, an optical character recognition module recognizing a set of alphanumeric characters within the determined location and a communication processor sending the recognized characters to a remotely located healthcare database.	03-17-2011

John M. Brackett, Kenosha, WI US

Patent application number	Description	Published
20080200515	SOLID STATE FORMS OF ENANTIOPURE ILAPRAZOLE - The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above.	08-21-2008
20080200516	SOLID STATE FORMS OF RACEMIC ILAPRAZOLE - The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(	08-21-2008
20080200517	CRYSTALLINE FORMS OF SOLVATED ILAPRAZOLE - The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.	08-21-2008
20110046184	SOLID STATE FORMS OF RACEMIC ILAPRAZOLE - The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.	02-24-2011
20110082174	SOLID STATE FORMS OF RACEMIC ILAPRAZOLE - The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.	04-07-2011